ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,615.35
0.55%
US Tech 100
19,804.00
0.64%
Dow Jones
40,000.90
0.62%
Brent Oil
84.57
0.00%
Bitcoin
58,879.66
1.71%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Arvinas Inc (ARVN) Quote

Arvinas Inc

Arvinas Inc (ARVN)

NASDAQ
28.87
0.25
(0.87%)
Closed July 13 4:00PM
Delayed by 15 minutes
28.87
0.00
(0.00%)
After Hours: 7:45PM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
28.87
Bid
28.88
Ask
31.00
Volume
812,910
28.43 Day's Range 30.27
13.57 52 Week Range 53.08
Market Cap
1.959B
Previous Close
28.62
Open
29.10
Last Trade
630
@
28.87
(priorref)
Last Trade Time
Financial Volume
$ 23,671,086
VWAP
29.119
Average Volume (3m)
843,942
Shares Outstanding
68,431,891
Dividend Yield
-
PE Ratio
-5.38
Earnings Per Share (EPS)
-5.37
Revenue
78.5M
Net Profit
-367.3M

About Arvinas Inc

Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-... Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. Its pipeline candidates include metastatic castration-resistant prostate cancer, metastatic ER-breast cancer, additional oncology indications, tauopathies, and other neurodegenerative diseases. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.arvinas.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Arvinas Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ARVN. The last closing price for Arvinas was $28.62. Over the last year, Arvinas shares have traded in a share price range of $ 13.57 to $ 53.08.

Arvinas currently has 68,431,891 shares outstanding. The market capitalization of Arvinas is $1.96 billion. Arvinas has a price to earnings ratio (PE ratio) of -5.38.

Arvinas (ARVN) Options Flow Summary

ARVN Options Flow

Overall Flow

Bearish

Net Premium

-216k

Calls / Puts

0.00%

Buys / Sells

100.00%

OTM / ITM

100.00%

Sweeps Ratio

0.00%

ARVN Latest News

More News

Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer

- Awards Mr. Saik an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - NEW HAVEN, Conn., June 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ: ARVN), a clinical-stage...

June 24 2024
GlobeNewswire Inc.

Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2

– Preclinical data for ARV-393 presented at the European Hematology Association 2024 Annual Congress showed anti-tumor activity in models of B-cell lymphoma –  – Preclinical data presented at the...

June 21 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

June 18 2024
Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities

June 18 2024
Edgar (US Regulatory)

Form 8-K - Current report

June 18 2024
Edgar (US Regulatory)

Form 8-K - Current report

June 17 2024
Edgar (US Regulatory)

Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer

NEW HAVEN, Conn., June 17, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation...

June 17 2024
GlobeNewswire Inc.

Arvinas to Participate in Upcoming Investor Conferences

NEW HAVEN, Conn., June 03, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation...

June 03 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

May 31 2024
Edgar (US Regulatory)

Form 8-K - Current report

May 30 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
15.0221.048218029423.8530.2723.3977908626.88758975CS
42.8110.782808902526.0630.2723.39100551325.90812218CS
12-5.22-15.312408330934.0937.3823.3984394229.50178713CS
26-9.81-25.361944157238.6853.0823.3978531736.63834917CS
525.2422.175201015723.6353.0813.5768465232.15917224CS
156-54.28-65.279615153383.15108.46513.5753124544.13970528CS
2603.7815.065763252325.09108.46513.5751567946.16866123CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
VEVVicinity Motor Corporation
$ 0.7131
(122.15%)
116.26M
QLGNQualigen Therapeutics Inc
$ 0.428851
(108.89%)
420.2M
IVPInspire Veterinary Partners Inc
$ 10.52
(88.19%)
41.79M
TOYOTOYO Company Ltd
$ 2.699
(74.13%)
56.65M
NISNNiSun International Enterprise Development Group Company Ltd
$ 9.11
(51.33%)
7.4M
SISIShineco Inc
$ 0.8446
(-60.16%)
6.71M
MCACMonterey Capital Acquisition Corporation
$ 3.54
(-49.50%)
364.7k
MCACUMonterey Capital Acquisition Corporation
$ 7.64
(-28.40%)
2.61k
GENEGenetic Technologies Ltd
$ 0.80
(-27.93%)
780.46k
KZIAKazia Therapeutics Ltd
$ 0.8975
(-27.62%)
25.62M
QLGNQualigen Therapeutics Inc
$ 0.428851
(108.89%)
420.2M
MAXNMaxeon Solar Technologies Ltd
$ 0.237
(-1.54%)
286.13M
NVDANVIDIA Corporation
$ 129.24
(1.44%)
251.65M
AGRIAgriFORCE Growing Systems Ltd
$ 0.1001
(21.92%)
192.82M
LCIDLucid Group Inc
$ 4.25
(25.00%)
167.79M

ARVN Discussion

View Posts
Monksdream Monksdream 5 months ago
ARVN new 52=week high
👍️0
Monksdream Monksdream 5 months ago
ARVN new 52 week high
👍️0
Monksdream Monksdream 5 months ago
ARVN new 52 week high
👍️0
Monksdream Monksdream 7 months ago
ARVN new 52 week high
👍️0
crudeoil24 crudeoil24 4 years ago
ARVN up 138% > "Based on data to date, we believe ARV-471 is the most promising ER-targeting therapy in the clinic, showing early signs of efficacy, a favorable tolerability profile, and better ER degradation than that previously reported for fulvestrant, the current standard of care,” said Ron Peck, Ph.D., Chief Medical Officer at Arvinas. “It is exciting to see that ARV-110 continues to be active and well tolerated in what we believe is the most heavily pretreated patient population that has ever been studied with an AR-directed therapy. Our recently initiated ARDENT Phase 2 cohort expansion is specifically designed to investigate the potential of a precision medicine approach in molecularly defined, late-line patients with few available treatment options, while also fully characterizing the safety and activity of ARV-110 in earlier line patients irrespective of molecular profile, setting ARV-110 on a potential two-pronged registrational path.”
👍️0
biocqr biocqr 5 years ago
Advantages of PROTACs vs. inhibition...

message_id=152832655
👍️0
G-lupo G-lupo 5 years ago
Idk about that, I thought it had some resistance and kept going through, I think at this next convention their going to release some positive news. I’m so holy I didn’t sell at $30 which was ceiling I thought. Do have in a $35 limit sell thought if drops. Rebuy anything under $25
👍️0
boo boo boo boo 5 years ago
Starting to see a chink in the armor!
👍️0
G-lupo G-lupo 5 years ago
Possibly wall at 30.50
👍️0
G-lupo G-lupo 5 years ago
I feel people are going to start taking profits before $35 price target and give it a dip back.
Question is what is that dip price
👍️0
boo boo boo boo 5 years ago
The offering:

8-k
👍️0
boo boo boo boo 5 years ago
Benzinga 11/14/2019:

With a rating of Buy, Roth Capital initiated coverage on Arvinas Inc (NASDAQ:ARVN). The price target is set at $35.00 for Arvinas. In the third quarter, Arvinas showed an EPS of $0.21, compared to ($62.38) from the year-ago quarter. The current market cap for Arvinas is at $696.1 million. The stock has a 52-week-high of $28.96 and a 52-week-low of $10.19. Arvinas's stock last closed at $28.38 per share.

I might post a chart in about a week, well after everything plays out!
👍️0
boo boo boo boo 5 years ago
It doesn't have to be a PR:

#8
👍️0
G-lupo G-lupo 5 years ago
Thanks, I’m in it, thought $28 would be resistant and broke through looks may break $30
👍️0
boo boo boo boo 5 years ago
https://polsonnews.com/arvinas-inc-nasdaqarvn-receives-34-33-average-pt-from-brokerages/
👍️0
G-lupo G-lupo 5 years ago
When did they Do a price target announcement? I didn’t see that.
👍️0
boo boo boo boo 5 years ago
If I were in this one (I'm not), I'd be finding the exit on the price target announcement.
👍️0
G-lupo G-lupo 5 years ago
Arvn looking good, defintely see $26-27
👍️0
G-lupo G-lupo 5 years ago
What you mean IBD?
👍️0
boo boo boo boo 5 years ago
Not me. I look for the trade setup. Learned of this one from IBD and have been following...waiting. Missed the opportunity by 1 day. Would've, Should've, Could've...
👍️0
G-lupo G-lupo 5 years ago
I agree I own a decent amount, purchased from $22 down to $15.50. In for the long haul
👍️0
boo boo boo boo 5 years ago
Missing a trade and people who post a purchase at a specific price well after that price has passed.

The bottom of the prior range (July thru September) is resistance as far as I'm concerned and you have a couple important SMA's around there. And I agree that a break of $27 could lead to a higher price. Wouldn't be as confident if a press release occurred at the same time, but then again depends on what is said.
👍️0
G-lupo G-lupo 5 years ago
What are you talking about ?

Saw the rebound at $16, going to get probably Around $25-26, if gets there look for resistance to drop back. Like this stock and with more news if breaks $27 could see $60
👍️0
boo boo boo boo 5 years ago
Screwed this one up. More and better content on biotech values board. And no, I don't think this individual bought 'yesterday' and posted about it the day after. That's crap and not credible...POSER!
👍️0
boo boo boo boo 5 years ago
Fook R's!

EOM
👍️0
boo boo boo boo 5 years ago
Price is at the 100 Lower Linear Regression channel. Do we consolidate here and eventually move north. No position...yet!
👍️0
PennyStock Alert PennyStock Alert 5 years ago
ARVN
👍️0
G-lupo G-lupo 5 years ago
This stock very volatile, no rhyme or reason why it’s been up and down.
👍️0
morokoy morokoy 5 years ago
Las Vegas man 1st in world to use new experimental cancer drug, ARV 101.

https://www.reviewjournal.com/life/health/las-vegas-man-1st-in-world-to-use-new-experimental-cancer-drug-video-1654750/
👍️0

Your Recent History

NASDAQ
ARVN
Arvinas
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved